妇科肿瘤III期临床试验中女性主要研究者比例趋势与地域差异
该研究检索ClinicalTrials.gov上2010至2020年启动的卵巢癌、子宫内膜癌和宫颈癌III期临床试验,共纳入200项,其中38%有女性担任主要研究者。女性担任PI的比例每年增加3%,多中心资助、非亚洲注册及多共同PI的试验中女性比例更高。
要点
- 200项III期妇科肿瘤试验中,38%有女性担任主要研究者。
- 女性PI比例每年增加3%,多中心资助和非亚洲注册试验中更高。
- 多共同PI的试验中女性担任PI的可能性更高。
核心结论
- 过去十年妇科肿瘤III期临床试验中女性主要研究者比例有所增加。
- 多来源资助且非亚洲注册的试验中女性PI比例最高。
研究设计与样本
- 通过姓名、机构网站照片或询问试验协调员确定PI性别。
- 使用卡方检验和相对风险比较组间比例,线性回归评估时间趋势。
主要发现
- 200项试验中76项(38%)有女性担任PI。
- 多中心资助试验中女性PI比例高于单一资助(RR=1.80,95%CI 1.25-2.61,p=0.01)。
- 非亚洲注册试验中女性PI比例高于亚洲(RR=1.78,95%CI 1.11-2.88,p=0.02)。
- 多共同PI试验中女性PI比例高于单一PI(RR=1.78,95%CI 1.18-2.67,p=0.01)。
- 女性PI比例按注册年份每年增加3%(R2=0.61,p=0.01),多洲和欧洲注册试验均每年增加4%。
临床怎么用
- 关注女性PI在妇科肿瘤临床试验中的代表性,促进领导机会。
- 多中心资助和非亚洲注册的试验可能提供更多女性领导机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the representation of women as principal investigators (PI) in phase 3, gynecologic oncology clinical trials. METHODS: ClinicalTrials.gov was queried for all phase 3 clinical trials with start dates between January 1, 2010 and December 31, 2020 using the search terms: "ovarian cancer", "endometrial cancer", and "cervical cancer". Trial characteristics were abstracted from the website. Gender of the PI was assessed by name, image on institutional website or by querying the trial coordinator. Trials were considered to have women's representation if women were the sole PI or among multiple co-PIs. Chi-square tests and relative risks were used to compare proportions across groups. Linear regression was used to assess trends over time. RESULTS: 200 unique clinical trials were included in this analysis, of which women were represented as PI in 76 (38%). Women were more likely to be a PI of trials funded by multiple sites than a single entity (RR = 1.80, 95% confidence interval (CI) 1.25, 2.61, p = 0.01), registered outside of Asia than those in Asia (RR = 1.78, 95% CI 1.11, 2.88, p = 0.02), and trials with multiple co-PIs than with one PI (RR = 1.78 (95% CI 1.18, 2.67), p = 0.01). Overall, women's representation as a PI increased by 3% annually (by year of registration, R2 = 0.61, p = 0.01). This increase was most evident in trials registered in multiple continents and Europe (both 4% annually). CONCLUSIONS: Women's representation as PIs in clinical trials has increased in the last decade. Trials funded by multiple sources outside of Asia have the highest proportion of PIs who are women. These trends may represent ongoing leadership and mentorship opportunities for women gynecologic oncologists.
引用
- Jou J, Brodsky A, Charo L, et al. Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials. Gynecol Oncol. 2021. PMID: 34099315. doi:10.1016/j.ygyno.2021.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。